СЧСветлана Вячеславовна Черкасова

Светлана Вячеславовна Черкасова

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Светлана Вячеславовна Черкасова has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Features of essential thrombocythemia in newborns and infants

    by L. D. Akhverdieva, D. M. Muscherova, H. A. Sarkisyan, S. V. Cherkasova, M. V. Dragunova, P. V. Shumilov

    Essential thrombocythemia (ICD-10: D47.3, OMIM: #187950) is a rare clonal myeloproliferative disorder characterized by a persistent increase in platelet count. The clinical course in newborns and young children is predominantly asymptomatic or oligosymptomatic, with a paradoxically low risk of thrombotic complications against a background of a high frequency of microvascular and haemorrhagic disorders caused by acquired von Willebrand syndrome. The diagnosis of essential thrombocythemia is complicated by the need to exclude reactive thrombocytosis and its hereditary forms, which are more common in the neonatal period. A promising direction at the moment is the development of paediatric diagnostic criteria and comprehensive genetic analyses to identify new driver mutations. Treatment is conservative and often leads to a favourable outcome. This review systematises current data from the world literature on the characteristics of essential thrombocythemia in newborns and young children, focusing on key differences from the adult form of the disease.

  • Features of hemorrhagic disease in newborns

    by A. A. Komarova, H. A. Sarkisyan, Y. V. Zhirkova, L. D. Vorona, S. V. Cherkasova, I. M. Burlakova, V. I. Materii, V. A. Mironova, L. M. Makarova, M. M. Nasser, et al.

    Hemorrhagic disorder of the newborn (or Vitamin K Deficiency Bleeding, VKDB) is a pathological condition caused by a deficiency of vitamin K, which is necessary for the synthesis of blood clotting factors, in children aged 8 days to 6 months. Vitamin K Deficiency Bleeding manifests as bleeding from various localizations. The late form of disease is typically diagnosed after the first week of life and can present as severe intracranial hemorrhages, which in turn can lead not only to residual neurological symptoms but also to fatal outcomes. This condition is observed in newborns who have not received prophylactic vitamin K administration at the delivery and are exclusively breastfed. This underscores the necessity for prevention, timely diagnosis, and treatment. Diagnosis is based on the medical history, clinical picture, and laboratory blood clotting analyses. The updated clinical recommendations for Vitamin K Deficiency Bleeding prevention have been implemented globally and in Russia, but the concerns of management children with late form of Vitamin K Deficiency Bleeding are still relevant. This article presents three clinical cases of full-term infants with late forms of Vitamin K Deficiency Bleeding. They did not receive prophylactic vitamin K administration and were exclusively breastfed. Special attention is given to the diagnosis and treatment of neurological disorders associated with intracranial hemorrhage, as well as the importance of timely prevention to avoid complications.

  • Noonan syndrome combined with juvenile xanthogranuloma in a newborn

    by D. M. Mushcherova, U. S. Severgina, A. P. Khokhlova, H. A. Sarkisyan, S. V. Cherkasova, E. I. Shabelnikova, P. V. Shumilov, Е. А. Саркисян

    RASopathies represent one of the largest groups of genetic disorders. One of them is Noonan syndrome, an autosomal dominant disease, which in rare cases can also be inherited in an autosomal recessive manner caused by a disruptions of the RAS/MAPK signaling pathway. This pathology occurs in 1 in 1000–2500 live births and leads to a number of disorders: dysmorphic facial features, congenital heart defects, lymphatic malformations, hemostatic disorders, chest abnormalities, cryptorchidism, delayed neuropsychological and physical development. The development of Noonan syndrome is caused by mutations in the genes PTPN11 (in about 50% of patients), SOS1, RAF1, RIT1, KRAS, NRAS, BRAF, LZTR1, SOS2, etc. The phenotypic similarity of Noonan syndrome to other RASopathies, as well as chromosomal abnormalities, in particular with Turner syndrome, the presence of concomitant pathology of the neonatal period and skin formations leads to difficulties in differential diagnostic search and, as a result, in diagnosis. Awareness of neonatologists and pediatricians about the clinical picture of this syndrome, as well as possible concomitant pathologies, will contribute to its early diagnosis, proper management strategies and improvement of the patient’s quality of life. This article describes a rare clinical case of juvenile xanthogranuloma in a child with Noonan syndrome.

  • Intrauterine thrombosis as a manifestation of antiphospholipid syndrome

    by S.V. Cherkasova, Moscow N.F.FIlatov Children’s City Clinical Hospital, A.I. Chubarova, M.A. Traube, A.V. Vorobev, N.R. Gashimova, K.N. Grigoreva, K.R. Pashayeva, N.YU. Feyziyeva, M.M. Baeva, et al.

    This article presents a rare case of intrauterine venous thrombosis as a result of antiphospholipid syndrome (APS). The clinical presentation, conditions and incidence, and comorbidities in neonates and children with APS differ significantly from those of adults with APS, leaving many cases of neonatal and pediatric APS undiagnosed. Therefore, a thorough analysis of each confirmed case of APS is necessary to develop new diagnostic criteria as well as to choose adequate therapeutic strategies with minimal risks for patients. Key words: neonatal antiphospholipid syndrome, intrauterine thrombosis, thrombophilia, placenta-related complications

  • Open Access

    NKX2-1-conditioned disorder — «brain–lung–thyroid» syndrome: results of a multicenter study

    by Валерия Алексеевна Стрельникова, Dmitry Yu. Ovsyannikov, Ольга Борисовна Кондакова, Людмила Михайловна Кузенкова, Шамиль Абдулвахидович Гитинов, Irina V. Girutskaya, Валерий Викторович Горев, Мария Александровна Жесткова, Надежда Ефимовна Кравченко, Екатерина Александровна Мамаева, et al.

    Introduction. Brain–lung–thyroid syndrome (BLTS, choreoathetosis and congenital hypothyroidism with or without pulmonary dysfunction) is an autosomal dominant disorder associated with mutations of the NKX2-1 gene. A triad of symptoms from three organs (brain, lungs, thyroid gland) is manifested in 50% of patients, in other cases there is an incomplete phenotype of the disease. The most common manifestations are neurological. The aim of the study was to provide genetic, clinical, laboratory, and instrumental characteristics in BLTS patients with a clinical and morphological assessment of the phenotype. Materials and methods. Ten children from 9 families with identified mutations in the NKX2-1 gene were observed. Methods used: genealogical, Sanger sequencing, clinical and morphological assessment of the phenotype, examination of thyroid hormone levels, CT, MRI of the brain, CT of the chest, lung biopsy. Results. The article presents the results of molecular genetic analysis, family history, age of manifestation and diagnosis. 9 out of 10 children had damage to the central nervous system, thyroid gland, lungs, and one child had a combination of neurological pathology and hypothyroidism. Neurological pathology was represented by benign hereditary chorea (2 children), delayed motor development (8), muscular hypotension (7), ataxia (5), choreoathetosis (1), clonuses (1), seizures (1), hyperkinesis (3); respiratory — respiratory distress syndrome (RDS) of newborns (6), chronic respiratory failure (5), interstitial lung disease (6), bronchial asthma (1), chronic pneumonitis of infants (1), bronchiectasis (1). There are presented changes in computed tomograms of the lungs and during preforming CT, MRI of the brain. Typical developmental microanomalia included a protruding forehead, a wide tip of the nose, elongated narrow palpebral fissure, deep-set eyes, hypertelorism of the eyes, large rotated low-lying auricles, conical fingers. Conclusion. A combination of congenital hypothyroidism, neonatal RDS, heart disease, neurological disorders (hypotension, ataxia, delayed motor development, chorea), craniofacial dysmorphia is the basis for a molecular genetic examination to exclude BLTS.

  • Beckwith–Wiedemann syndrome in the practice of neonatologist and pediatric surgeon

    by D.M. Mushcherova, H.A. Sarkisyan, P.V. Shumilov, L.D. Vorona, Moscow V.F.VOyno-Yasenetsky Scientific And Practical Center Of Specialized Medical Care For Children, A.P. Khokhlova, L.A. Levchenko, S.V. Cherkasova, A.S. Ilyushkina, Yu.L. Ishutina, et al.

    Beckwith–Wiedemann syndrome is the most frequent congenital anomaly (1 in 13,700 live births worldwide) manifested by overgrowth at the early stages of development. The syndrome is characterized by a complex type of inheritance and is due to a number of different genetic causes and epigenetic changes leading to impaired transcription of growth regulatory genes located on the short arm of chromosome 11. The clinical presentation varies widely, but the main diagnostic criteria include macrosomia, macroglossia, anterior abdominal wall defects, visceromegaly, and unusual facial features (hypoplasia of the middle third, hemangioma of the forehead skin, creases in the earlobe). The danger of the pathology lies in possible complications, including neonatal hypoglycemia and a high incidence of fetal tumors, which determines the need for early diagnosis of the syndrome and further long-term follow-up of a child. This article presents a rare clinical case of Beckwith–Wiedemann syndrome in a newborn with persistent hypoglycemia who underwent a unique surgery to correct macroglossia. Key words: macroglossia, macrosomia, neonatal hypoglycemia, omphalocele, Beckwith–Wiedemann syndrome, overgrowth syndromes, partial glossectomy

  • Current approaches to the diagnosis and management of Beckwith–Wiedemann syndrome in newborns

    by A.P. Khokhlova, D.M. Mushcherova, H.A. Sarkisyan, L.D. Vorona, Moscow V.F.VOyno-Yasenetsky Scientific And Practical Center Of Specialized Medical Care For Children, L.A. Levchenko, S.V. Cherkasova, A.S. Ilyushkina, E.S. Nifatova, P.V. Shumilov

    Beckwith–Wiedemann syndrome (OMIM 130650, Q87.3) is a congenital anomaly characterized by overgrowth. It has a wide range of clinical manifestations, but the three main features include macrosomia, macroglossia, and anterior abdominal wall defect. The prevalence of the disease is 1 in 13,700 newborns worldwide, equally represented in males and females. Epigenetic and genetic changes on chromosome 11p15.5 are etiological factors: loss of maternal methylation at IC2 (KCNQ1OT1), paternal uniparental disomy, mutation in the CDKN1C gene, maternal hypermethylation at IC1 (H19), cytogenetically visible duplication of chromosome 11p15, and translocation/inversion of chromosome 11p15. Genetic heterogeneity and the possibility of cellular mosaicism in this syndrome cause phenotypic differences between patients, as well as the complexity of molecular genetic confirmation. An important aspect in the management of patients with Beckwith-Wiedemann syndrome is timely detection and correction of hypoglycemia as a predictor of neurological deficit, as well as long-term monitoring for early detection of malignant neoplasms, including Wilms tumor. Treatment is currently symptomatic, including therapeutic and surgical management, but potential approaches to targeted therapy are being explored. Timely diagnosis of the disease improves longterm outcomes and quality of life of children with this pathology. This article presents current approaches to the diagnosis and management of Beckwith–Wiedemann syndrome in newborns. Key words: genomic imprinting disorders, hypoglycemia, anterior abdominal wall defect, macroglossia, macrosomia, Wilms tumor, Beckwith–Wiedemann syndrome

  • Open Access

    The method of thrombodynamics in the diagnosis of thrombosis in high-risk newborns

    by Moscow N.F. Filatov Children’s City Hospital, S.V. Cherkasova, A.I. Chubarova

    Метод тромбодинамики в диагностике тромбозов у новорожденных высокого риска

  • Hemorrhagic disease of the newborn: modern approaches to diagnosis, prevention and treatment

    by E.M. Rashkova, A.A. Shakirova, H.A. Sarkisyan, L.A. Levchenko, S.V. Cherkasova, E.I. Shabelnikova

    Background. Hemorrhagic disease of the newborn is a pathological condition in newborns and children during the first months of life, caused by vitamin K deficiency of dependent blood coagulation factors and manifested by increased bleeding. The incidence of hemorrhagic disease of the newborn varies in different regions of the world, in Russia, according to the literature data, it ranges from 0.25 to 1.7%. Hemorrhagic disease of the newborn is characterized by the development of bleeding and hemorrhage, which negatively affect the function and further development of a number of organs and systems of the child, especially the central nervous system and the gastrointestinal tract. Based on the etiology of the development of the disease described above, HDN is classified into primary (idiopathic) and secondary. Depending on the age of onset, early is distinguished – it manifests itself in the first 24 hours of life, classical – develops on the 2-7th day and late, manifesting itself after 1 week of life (rarely occurs at the age of up to 6 months of life, and some authors indicate the age children under 1 year of age) hemorrhagic disease of the newborn forms. The key priority of neonatologists is to single out from the number of born children, newborns who are at risk for HRD for the purpose of prophylactic administration of vitamin K to them, which will prevent severe undesirable consequences of the disease.A genetic study using logistic regression analysis confirmed a higher risk of intraventricular hemorrhages in newborns with polymorphisms in the VKORC1 genes, which is responsible for the binding of vitamin K1 to cysteine, and thus for a decrease in its concentration in carriers of this gene. Despite the variability in approaches to doses, methods and timing of administration, parenteral administration of vitamin K is the only reliable and preferred way to prevent this disease. In the case of the development of hemorrhagic disease of the newborn, modern approaches to the diagnosis and treatment of this pathology have been developed. Results. The article presents modern approaches to the prevention, diagnosis and therapy of vitamin K-dependent hemorrhagic disease of the newborn.


  • Hereditary tyrosinemia type 1 in an infant with multiple congenital defects

    by H.A. Sarkisyan, S.V. Cherkasova, A.A. Fadeeva, A.S. Yarushnikova, Y.S. Piliuzina, A.B. Smolyannikova, E.I. Shabelnikova, L.M. Makarova, M.A. Ovsyannikova, L.A. Levchenko, et al.

    Hereditary tyrosinemia type 1 or hepatorenal tyrosinemia is a severe orphan autosomal-recessive disorder of tyrosine metabolism caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH). The disease is diagnosed in approximately 1:100 000-1:120 000 cases of live births, and in certain regions (such as the Chechen Republic in Russian Federation) the estimated frequency of diagnosis can be significantly higher. In hereditary tyrosinemia type 1, blood levels of tyrosine, succinylacetone and other toxic metabolites are increased, which results in the accumulation of the toxic metabolites in target organs causingliver damage with progressive development of liver failure and liver cirrhosis, damage to the renal tubules resulting in Fanconi syndrome and hypophosphatemic rickets, and central nervous system. In some patients, myocardium could be involved in the pathological process, resulting in the development of hypertrophic cardiomyopathy. The disease presents a great challenge for differential diagnosis due to its polyorganic nature and frequent combination with other hereditary disorders. The modern treatment of hereditary tyrosinemia type 1 includes an elimination-based diet and pathogenetic drug therapy. The potential of genetic engineering methods in target therapy of hereditary tyrosinemia type 1 is being actively researched. Within the article if presented a case of early onset hereditary tyrosinemia type 1 in an infant with multiple congenital defects of central nervous system, including Dandy – Walker syndrome, and congenital defects of maxillofacial area, with signs of an immunodeficiency state and a severe generalized recurring infectious process involving poly-resistant mixed flora. The dynamic changes of neurologic signs are provided for the first year of life of the patient receiving the pathogenetic therapy for the main disease. Laboratory findings are provided, showing the dynamic changes in liver function of the patient.